Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6LZG

Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2

Summary for 6LZG
Entry DOI10.2210/pdb6lzg/pdb
DescriptorAngiotensin-converting enzyme 2, Spike protein S1, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
Functional Keywordsnovel coronavirus, spike protein, receptor, viral protein
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight93502.21
Authors
Wang, Q.H.,Song, H.,Qi, J.X. (deposition date: 2020-02-19, release date: 2020-03-18, Last modification date: 2024-11-06)
Primary citationWang, Q.,Zhang, Y.,Wu, L.,Niu, S.,Song, C.,Zhang, Z.,Lu, G.,Qiao, C.,Hu, Y.,Yuen, K.Y.,Wang, Q.,Zhou, H.,Yan, J.,Qi, J.
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.
Cell, 181:894-904.e9, 2020
Cited by
PubMed Abstract: The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.
PubMed: 32275855
DOI: 10.1016/j.cell.2020.03.045
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

236963

PDB entries from 2025-06-04

PDB statisticsPDBj update infoContact PDBjnumon